-
4 days ago | 
nature.com | Delphine Lebon |Nicolas Duployez |Christophe Willekens |Thomas Cluzeau |Christian Récher |Mathilde Hunault-Berger | +1 more
AbstractFront-line treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in patients with low-/intermediate-risk acute promyelocytic leukemia (APL). However, for high-risk (HR) patients (defined as those with a white blood cell count ≥ 10×10⁹/L), the role of ATRA-ATO is subject to debate, and study data are scarce.
-
2 months ago | 
flipboard.com | Alexis Bisson |Stanislas de Livonnière |Thomas Cluzeau |Victor Alexandre
1 hour agoAffaire des emplois fictifs : François Fillon de retour devant la justiceFrançois Fillon a une nouvelle fois rendez-vous ce mardi au tribunal. Huit ans après la révélation de l’affaire des emplois fictifs de son épouse …2 hours agoDes fans de l’OM dans le vestiaire à Paris !Pur produit de l’OM, Maxime Lopez a posé ses valises à Paris l’été dernier. En effet, le milieu de terrain a rejoint son frère au Paris FC.
-
Aug 16, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.
-
Aug 16, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 16, 2024Author(s):The expert panel explores the future landscape of lower-risk myelodysplastic syndrome treatment, considering recent approvals and emerging clinical data. Video content above is prompted by the followingWhat does the future of lower-risk MDS treatment look like? Following the latest approvals, guideline updates, and emerging data:How does this impact your future treatment strategies?
-
Aug 9, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 9, 2024Author(s):Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations. Please comment on which patients you would consider 2L imetelstat for patients with LR-MDS. Please provide a summary of the IMerge study, evaluating imetelstat in patients that R/R to ESAs in LR-MDS. (Platzbecker U, Santini V, Fenaux P, et al. Lancet.
-
Aug 9, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 9, 2024Author(s):Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application. Focusing on real-world evidence (RWE), how do outcomes compare what’s seen in practice and how does that impact your choice of therapy? Real-world dose escalation and outcomes of luspatercept across all LOTs (Patel K, et al. EHA 2024.
-
Aug 2, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 2, 2024Author(s):Medical experts discuss sequencing strategies for second-line and later treatments in lower-risk myelodysplastic syndromes, examining how recent data, including insights from the MEDALIST trial, influence treatment selection and sequencing decisions. Let’s explore sequencing strategies for lower-risk MDS in the 2L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
-
Aug 2, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 2, 2024Author(s):Medical experts explore alternative treatment options for lower-risk myelodysplastic syndrome (LR-MDS) patients who are not suitable candidates for first-line luspatercept therapy. For patients who are not suitable to receive 1L luspatercept for LR-MDS, what alternate treatment options would you consider? What other trials on the horizon are you excited for in the 1L treatment of lower-risk MDS?
-
Jul 29, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoJuly 29, 2024Author(s):Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions. Briefly comment on the safety profile of available frontline treatments for patients with LR-MDS. How would you mitigate those events in your practice? How does toxicities observedimpact your overall treatment selection for patients?
-
Jul 29, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
